Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
Abstract Elevated low-density lipoprotein cholesterol (LDL-C) level is associated with an increased risk of atherosclerotic cardiovascular disease. Although high-intensity lipid-lowering therapies with statins and ezetimibe are highly effective for reducing LDL-C levels, over half of high-risk patie...
Main Author: | Toshiyuki Nishikido |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-01-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12933-023-01752-4 |
Similar Items
-
Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran
by: Michael J. Wilkinson, et al.
Published: (2024-03-01) -
Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies
by: Arrigo F.G. Cicero, et al.
Published: (2022-01-01) -
Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
by: Niki Katsiki, et al.
Published: (2023-04-01) -
Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
by: Constantine E. Kosmas, et al.
Published: (2018-07-01) -
Effects of Serum Estradiol on Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Lipid Profiles in Women Undergoing In Vitro Fertilization
by: Anna Papanikolaou, et al.
Published: (2024-01-01)